Acute ischemic stroke is one of the main diseases leading to high risk of disability and morbidity worldwide. Since intravenous thrombolysis(IVT) can effectively improve the long-term functional prognosis of acute ischemic stroke(AIS), IVT within 4.5 hours of onset has been widely recommended by international guidelines.

Although 35-53% of AIS patients achieve functional independence after receiving IVT, there are still a large number of patients who are disabled or even dead, and nearly 70% of patients have ineffective recanalization. Therefore, there is an urgent need for therapeutic drugs after IVT to further improve the prognosis and reduce the burden of AIS.

Shuxuetong injection is widely used in China in patients with AIS after IVT, but the situation in real clinical practice is unclear. Therefore, the study aims to evaluate the effectiveness and safety of Shuxuetong Injection in patients with AIS treated with intravenous alteplase and tenecteplase, and obtain high-quality clinical evidence.

Inclusion Criteria:

• Hospitalized patients aged ≥18 years
• Diagnosis of acute ischemic stroke
• Receiving alteplase or tenecteplase treatment ≤ 4.5 hours of onset
• Signed informed consent by patient or legally authorized representatives

Exclusion Criteria:

• Having received or planing to undergo endovascular therapy (including mechanical thrombectomy, arterial thrombolysis, angioplasty, etc.)
• Life expectancy is less than 90 days
• Other factors that the researchers think are not suitable for participating in the research
• Currently receiving any experimental treatment

Patients with acute ischemic stroke who received alteplase or tenecteplase within 4.5 hours of onset